Triamcinolone Acetonide
JFDA label: Panbicort 40mg Inj.
Mechanism of Action
Agonist of Glucocorticoid receptor — Glucocorticoid receptor agonist
| Target | Action | Gene / class |
|---|---|---|
| Glucocorticoid receptor efficacy | AGONIST | NR3C1 |
Indications
Approved
- Anemia — anemia
- Arthritis, Gouty — gout
- Arthritis, Rheumatoid — rheumatoid arthritis
- Asthma — asthma
- Bursitis — frozen shoulder
- Dermatitis — dermatitis
- Multiple Sclerosis — multiple sclerosis
- Mycoses — fungal infectious disease
- Nasal Obstruction — Nasal congestion
- Osteoarthritis — osteoarthritis
- Pain — pain
- Rhinitis, Allergic, Seasonal — seasonal allergic rhinitis
- Serum Sickness — type III hypersensitivity reaction disease
- Skin Diseases — skin disease
- Tennis Elbow — lateral epicondylitis
- Tenosynovitis — tenosynovitis
- Tuberculosis, Pulmonary — pulmonary tuberculosis
- Wounds and Injuries — injury
Off-label
- Alopecia Areata
- Breast Neoplasms
- Cataract
- Chalazion
- Choroidal Neovascularization
- Complex Regional Pain Syndromes
- Cough
- Cystitis, Interstitial
- Dermatitis, Atopic
- Diabetic Retinopathy
- Dupuytren Contracture
- Eye Injuries
- Glaucoma
- Hand Dermatoses
- Humeral Fractures
- Keloid
- Lichen Planus
- Lichen Planus, Oral
- Macular Degeneration
- Macular Edema
- Optic Neuropathy, Ischemic
- Osteoarthritis, Hip
- Osteoarthritis, Knee
- Otitis Media with Effusion
- Pemphigoid, Benign Mucous Membrane
- Pemphigus
- Psoriasis
- Radiculopathy
- Retinal Vein Occlusion
- Rhinitis
- Shoulder Pain
- Tendinopathy
- Ulnar Neuropathies
- Uveal Melanoma
- Uveitis
- Uveomeningoencephalitic Syndrome
- Vitiligo
- Vitreoretinopathy, Proliferative
- Wet Macular Degeneration
Contraindications
Source: openFDA
- Triamcinolone acetonide injectable suspension is contraindicated in patients who are hypersensitive to any components of this product (see WARNINGS: General ). Intramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura. Absolute
Adverse Reactions
Nervous system disorders (3)
Very Common Headache
Rare Dizziness · Glaucoma
Immune system disorders (2)
Rare Anaphylactic shock · Hypersensitivity
Endocrine disorders (1)
Rare Blood cortisol decreased
Gastrointestinal disorders (3)
Common Diarrhoea · Dyspepsia
Rare Nausea
Skin and subcutaneous tissue disorders (3)
Common Dermatitis · Rash
Rare Pruritus
Musculoskeletal and connective tissue disorders (1)
Common Back pain
Psychiatric disorders (1)
Rare Insomnia
Infections and infestations (7)
Very Common Pharyngitis · Rhinitis
Common Bronchitis · Infection · Influenza · Nasopharyngitis · Sinusitis
Investigations (1)
Common Body temperature increased
General disorders and administration site conditions (10)
Very Common Sneezing
Common Excoriation · Pain · Tooth disorder
Uncommon Oropharyngeal discomfort · Oropharyngeal pain · Sinus congestion
Rare Asthenia · Cataract · Fatigue
Respiratory, thoracic and mediastinal disorders (7)
Very Common Epistaxis
Common Asthma · Cough · Laryngeal pain · Nasal discomfort · Rhinorrhoea
Rare Dyspnoea
Dosing
Source: openFDA
Warnings & Precautions
Source: openFDA
Warnings & Precautions
Serious Neurologic Adverse Reactions with Epidural Administration Serious neurologic events, some resulting in death, have been reported with epidural injection of corticosteroids (see WARNINGS: Neurologic ). Specific events reported include, but are not limited to, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke. These serious neurologic events have been reported with and without use of fluoroscopy. The safety and effectiveness of epidural administration of corticosteroids have not been established, and corticosteroids are not approved for this use. General Exposure to excessive amounts of benzyl alcohol has been associated with toxicity (hypotension, metabolic acidosis), particularly in neonates, and an increased incidence of kernicterus, particularly in small preterm infants. There have been rare reports of deaths, primarily in preterm infants, associated with exposure to excessive amounts of benzyl alcohol. The amount of benzyl alcohol from medications is usually considered negligible compared to that received in flush solutions containing benzyl alcohol. Administration of high dosages of medications containing this preservative must take into account the total amount of benzyl alcohol administered. The amount of benzyl alcohol at which toxicity may occur is not known. If the patient requires more than the recommended dosages or other medications containing this preservative, the practitioner must consider the daily metabolic load of benzyl alcohol from these combined sources (see PRECAUTIONS: Pediatric Use ). Rare instances of anaphylaxis have occurred in patients receiving corticosteroid therapy (see ADVERSE REACTIONS ). Cases of serious anaphylaxis, including death, have been reported in individuals receiving triamcinolone acetonide injection, regardless of the route of administration. Because triamcinolone acetonide injectable suspension is suspension, it should not be administered intravenously. Unless a deep intramuscular injection is given, local atrophy is likely to occur. (For recommendations on injection techniques, see DOSAGE AND ADMINISTRATION .) Due to the significantly higher incidence of local atrophy when the material is injected into the deltoid area, this injection site should be avoided in favor of the gluteal area. Increased dosage of rapidly acting corticosteroids is indicated in patients on corticosteroid therapy subjected to any unusual stress before, during, and after the stressful situation. Tri
Chemistry & Properties
| Formula | C24H31FO6 |
|---|---|
| Molecular weight | 434.5 g/mol |
| IUPAC name | (1S,2S,4R,8S,9S,11S,12R,13S)-12-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one |
| CAS | 76-25-5 |
| PubChem CID | 6436 |
| InChIKey | YNDXUCZADRHECN-JNQJZLCISA-N |
| logP | 2.42 (XLogP 2.5) |
| Polar surface area | 93.06 Ų |
| H-bond acceptors / donors | 6 / 2 |
| Drug-likeness (QED) | 0.69 |
| Lipinski violations | 0 |
SMILES
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1Biology & Pharmacokinetics
Pharmacokinetics
| BBB penetrant | Yes |
|---|
Enzyme interactions
| Enzyme | Role | Detail |
|---|---|---|
| CYP2C8 | Inhibitor | — |
| CYP3A4 | Substrate | — |
Receptor binding (top 1)
| Target | Action | Affinity |
|---|---|---|
| Glucocorticoid receptor (NR3C1) | Agonist | pIC50 8.2 |
Transporters
BCRP (Inhibitor)BCRP (Inhibitor)BSEP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)MRP3 (Inhibitor)MRP4 (Inhibitor)OATP1B1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)P-gp (Substrate)
Registered Products (6)
| Brand | Form / strength | Pack | Agent | Citizen (JOD) |
|---|---|---|---|---|
| Panderm Cream | Cream 10.000000 IU/100 g, 0.025 g/100 g, 0.25 g/100 g, 0.1 g/100 g | 15 g tube pack varies | Professional Drug Store | 1.420 |
| Kenaphil Cream | Cream 0.326 g/tube, 0.00375 g/tube, 0.055161 g/tube, 0.015 g/tube | 15 g tube | PHILADELPHIA PHAEMACEUTICALS.COMP/JORDAN | 1.510 |
| Ecorex Plus Cream | Cream 1 %, 0.1 % | 15 g tube pack varies | Hayat Pharmaceutical Industries CO.PLC/JORDAN | 1.690 |
| Panderm Cream | Cream 10.000000 IU/100 g, 0.025 g/100 g, 0.25 g/100 g, 0.1 g/100 g | 30 g tube pack varies | Professional Drug Store | 2.480 |
| Ecorex Plus Cream | Cream 1 %, 0.1 % | 30 g tube pack varies | Hayat Pharmaceutical Industries CO.PLC/JORDAN | 3.210 |
| Panbicort 40mg Inj. | Injection 40 mg/ml | 1 ml | AL Rahma Drug Store | 14.680 |